Novartis Investigative Site

Saint Clair Shores, Michigan 48081

0 studies enrolling now · 2 studies all time

What they study most

Ankylosing Spondylitis, Arthritis, Psoriatic

Studies at this site

• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis — Completed
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis — Completed